Nefrología y neurología

Sánchez, Gerardo Alfonso Márquez; Gómez, María Fernanda; Gómez, María Pilar Fraile; Núñez, Juan F. Macías; Martinez, Ana Isabel; Álvarez, Cristina Lucas; Miguel, José Antonio Menacho; Arribas, Alberto Martín; Garrido, Tamara García; Villar, Julio Herrera Pérez del; Diez, Julia Teresa Herrera; García, Karen Rivero; Tyszkiewicz, Anika; Tostón, Oscar Segurado; Márquez, José Luis Lerma; Molina, Fernando Tornero; Pérez-Monteoliva, Nicolás Roberto Robles; Sánchez-Jauregui, Miguel; Zhindón, Gabriela del Pilar González; Tabernero, Guadalupe; Musso, Carlos Guido; Gregori, Joaquin Antonio Alvarez; Centellas, Jesús Martín; Álvarez, Carlota Durán; Fernández, Bárbara Yolanda Padilla; Martínez, Lauro Sebastián Valverde; García, Ana Gómez; Sánchez, Magaly Teresa Márquez; Huertos, Ana María Nieto; Cárdenes, Alberto Rivero; Pérez, Cristina Salvatierra; Vicente, A. Gil; Canelo, José Antonio Mirón; Parada, Alejandro Martín

doi:10.14201/0mu0097

Cited by 2 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prostate cancer (International Classification of Diseases [ICD] 10 C61 Malignant tumour of the prostate) is the glandular epithelial cells' abnormal and disordered growth that can spread [1,2].…”

Section: Introductionmentioning

confidence: 99%

“…Its incidence increases with age, and it is rarely diagnosed in patients under 50. It is estimated that around 200,000 new cases are diagnosed every year, and one in five has a fatal evolution [2]. Worldwide, there were an estimated 1.4 million diagnoses in 2020 [3,4].…”

Section: Introductionmentioning

confidence: 99%

“…In their review, they address the resistance to abiraterone acetate and enzalutamide with special interest in androgen receptor (AR) splice variants (AR-Vs) such as AR-V7 [15]. They concluded that, given the available evidence, the study of these variants can be useful in predicting and treating metastatic castration-resistant prostate cancer (mCRPC) [2].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Evaluation and Effectiveness of Clinical Trials with Hormone Therapy in the Treatment of Prostate Cancer

et al. 2022

View full text Add to dashboard Cite

Background: Prostate cancer is currently the most common malignant tumour in men. Research on hormone therapy advances is necessary because, unfortunately, some tumours are not organ-confined. Objective: To review and analyse the current state of evidence regarding clinical trials with neoadjuvant or adjuvant hormone therapy for prostate cancer and determine the contribution of these trials to the clinical practice. Methods: A critical systematic analysis of hormone therapy clinical trials for prostate cancer in the American Society of Clinical Oncology (ASCO) 2022 official database was carried out and following the Cochrane Handbook for Systematic Reviews of Interventions, a meta-analysis of random effects and standard mean descriptive statistics were performed. Groups: Group A = Neoadjuvant (n = 53) clinical trials and Group B = Adjuvant (n = 73) clinical hormone therapy. Variables: Phase of the trial, modality of primary treatment, investigated intervention or drug, molecular targets, trial length, sponsors and collaborators, country/countries of trial development, estimated enrolment, assignment of patients, intervention and masking model, trial purpose, related articles, the average number of studied patients, and conclusive results in clinical practice. Results: A total of 7.15% of the studies were in phase I, 14.28% between phase I-phase II, 52.38% in phase II, 0.23% between phase II-phase III and 23.80% in phase III. In the neoadjuvant group, enzalutamide and abiraterone were more frequently used, the androgen receptor was more frequently investigated as a molecular target. In the adjuvant group, abiraterone and prednisone were more frequently used and the androgen receptor and cytochrome P450 were more frequently investigated. The mean number of articles related to each trial was 5.26 (SD 3.15, 1–10). In 47.27% of the published articles directly related to the trials, the investigated treatment was superior to the standard treatment. Adjuvant investigated drugs showed more superiority (52.22%) than neoadjuvant drugs (41.33%). Conclusions: Only 41.33% of neoadjuvant studies and 52.22% of adjuvant studies show conclusive results of superiority for the proposed therapeutic strategies. About a third of related scientific publications that transfer the results to clinical practice did not report conclusive results for either neoadjuvant (32%) or adjuvant (37.78%) therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation and Effectiveness of Clinical Trials with Hormone Therapy in the Treatment of Prostate Cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

Relationship between Mental Disorders, Smoking or Alcoholism and Benign Prostate Disease

Chantada-Tirado,

Chantada-Abal,

Cózar-Ortiz

et al. 2024

Clinics and Practice

View full text Add to dashboard Cite

Introduction: Mental disorders, smoking, or alcoholism and benign prostate disease are highly prevalent in men. Aims: To identify the relationship between mental disorders, smoking, or alcoholism and benign prostate disease. Methodology: A prospective multicenter study that evaluated prostate health status in 558 men from the community. Groups: GP—men who request a prostate health examination and whose medical history includes a mental disorder, smoking, or alcoholism prior to a diagnosis of benign prostate disease; GU—men who request a prostate health examination and whose medical history includes a benign prostate disease prior to a diagnosis of mental disorder, smoking, or alcoholism. Variables: age, body mass index (BMI), prostate specific antigen (PSA), follow-up of the mental disorder, smoking or alcoholism, time elapsed between urological diagnosis and the mental disorder, smoking or alcoholism diagnosis, status of the urological disease (cured or not cured), concomitant diseases, surgical history, and concomitant treatments. Descriptive statistics, Student’s t-test, Chi2, multivariate analysis. Results: There were no mental disorders, smoking, or alcoholism in 51.97% of men. Anxiety, smoking, major depressive disorder, pathological insomnia, psychosis, and alcoholism were identified in 19.71%, 13.26%, 5.73%, 4.30%, 2.87%, and 2.15% of individuals, respectively. Nonbacterial prostatitis (31.54%), urinary tract infection (other than prostatitis, 24.37%), prostatic intraepithelial neoplasia (13.98%), and prostatodynia (1.43%) were prostate diseases. Unresolved symptomatic benign prostate disease was associated with anxiety, depression, and psychosis (p = 0.002). Smoking was the disorder that men managed to eliminate most frequently. The dominant disorder in patients with symptomatic benign prostatic disease was alcoholism (p = 0.006). Conclusions: Unresolved symptomatic benign prostatic disease is associated with anxiety, depression, and psychosis. Alcoholism is associated with a worse prognosis in the follow-up of symptomatic benign prostatic disease.

show abstract

Nefrología y neurología

Cited by 2 publications

References 0 publications

Evaluation and Effectiveness of Clinical Trials with Hormone Therapy in the Treatment of Prostate Cancer

Evaluation and Effectiveness of Clinical Trials with Hormone Therapy in the Treatment of Prostate Cancer

Relationship between Mental Disorders, Smoking or Alcoholism and Benign Prostate Disease

Contact Info

Product

Resources

About